U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H22ClF2N3O
Molecular Weight 393.858
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BEFIRADOL

SMILES

CC1=CC=C(CNCC2(F)CCN(CC2)C(=O)C3=CC=C(F)C(Cl)=C3)N=C1

InChI

InChIKey=PKZXLMVXBZICTF-UHFFFAOYSA-N
InChI=1S/C20H22ClF2N3O/c1-14-2-4-16(25-11-14)12-24-13-20(23)6-8-26(9-7-20)19(27)15-3-5-18(22)17(21)10-15/h2-5,10-11,24H,6-9,12-13H2,1H3

HIDE SMILES / InChI

Molecular Formula C20H22ClF2N3O
Molecular Weight 393.858
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Befiradol (also known as NLX-112) was initially developed by Pierre Fabre as a selective serotonin-1A receptor agonist for the treatment of cancer pain and neuropathic pain. However, these trials were discontinued. In 2013, the development and commercialization rights were licensed to Neurolixis. Neurolixis studied befiradol in Parkinson’s disease (PD) patients that exhibit dyskinesia. Dyskinesia is a side effect that appears after several years of action Levodopa, a drug that remains the gold standard treatment for PD. In 2019, FDA gave a positive response to Neurolixis’s befiradol to be tested in Phase 2 clinical in Parkinson's disease patients suffering from debilitating levodopa-induced dyskinesia.

Approval Year

PubMed

PubMed

TitleDatePubMed
High-efficacy 5-hydroxytryptamine 1A receptor activation counteracts opioid hyperallodynia and affective conditioning.
2006 Feb
Patents
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:13:27 UTC 2023
Edited
by admin
on Fri Dec 15 17:13:27 UTC 2023
Record UNII
RAT9OHA1YH
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BEFIRADOL
INN   WHO-DD  
INN  
Official Name English
Befiradol [WHO-DD]
Common Name English
F-13640
Code English
(3-CHLORO-4-FLUOROPHENYL)(4-FLUORO-4-((((5-METHYLPYRIDIN-2-YL)METHYL)AMINO)METHYL)PIPERIDIN-1-YL)METHANONE
Systematic Name English
NLX-112
Code English
befiradol [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C241
Created by admin on Fri Dec 15 17:13:27 UTC 2023 , Edited by admin on Fri Dec 15 17:13:27 UTC 2023
Code System Code Type Description
PUBCHEM
9865384
Created by admin on Fri Dec 15 17:13:27 UTC 2023 , Edited by admin on Fri Dec 15 17:13:27 UTC 2023
PRIMARY
ChEMBL
CHEMBL45305
Created by admin on Fri Dec 15 17:13:27 UTC 2023 , Edited by admin on Fri Dec 15 17:13:27 UTC 2023
PRIMARY
CAS
208110-64-9
Created by admin on Fri Dec 15 17:13:27 UTC 2023 , Edited by admin on Fri Dec 15 17:13:27 UTC 2023
PRIMARY
NCI_THESAURUS
C81392
Created by admin on Fri Dec 15 17:13:27 UTC 2023 , Edited by admin on Fri Dec 15 17:13:27 UTC 2023
PRIMARY
EVMPD
SUB189251
Created by admin on Fri Dec 15 17:13:27 UTC 2023 , Edited by admin on Fri Dec 15 17:13:27 UTC 2023
PRIMARY
INN
8953
Created by admin on Fri Dec 15 17:13:27 UTC 2023 , Edited by admin on Fri Dec 15 17:13:27 UTC 2023
PRIMARY
SMS_ID
100000175063
Created by admin on Fri Dec 15 17:13:27 UTC 2023 , Edited by admin on Fri Dec 15 17:13:27 UTC 2023
PRIMARY
EPA CompTox
DTXSID90943058
Created by admin on Fri Dec 15 17:13:27 UTC 2023 , Edited by admin on Fri Dec 15 17:13:27 UTC 2023
PRIMARY
FDA UNII
RAT9OHA1YH
Created by admin on Fri Dec 15 17:13:27 UTC 2023 , Edited by admin on Fri Dec 15 17:13:27 UTC 2023
PRIMARY
WIKIPEDIA
BEFIRADOL
Created by admin on Fri Dec 15 17:13:27 UTC 2023 , Edited by admin on Fri Dec 15 17:13:27 UTC 2023
PRIMARY
Related Record Type Details
TARGET -> AGONIST
SALT/SOLVATE -> PARENT
LABELED -> NON-LABELED
Related Record Type Details
ACTIVE MOIETY